In the rapidly expanding weight-loss drug market, telehealth provider Hims & Hers Health, Inc. (NYSE:HIMS) has found a niche by offering affordable alternatives to popular anti-obesity medications like Eli Lilly And Co’s (NYSE:LLY) Zepbound and Novo Nordisk A/S’ (NYSE:NVO) Wegovy.
These alternatives cater to customers who are either unable to access the original drugs due to shortages or are deterred by their high costs.
However, concerns are growing over the sustainability of this business model, especially as big pharmaceutical companies ramp up production to meet demand.
Also Read: BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race.
Hims & Hers has significantly ...
